chloroquine has been researched along with Acute Rheumatic Fever in 25 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 23 (92.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (8.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
RODRIGUE, C | 1 |
Abud-Mendoza, C | 1 |
de la Fuente, H | 1 |
Cuevas-Orta, E | 1 |
Baranda, L | 1 |
Cruz-Rizo, J | 1 |
González-Amaro, R | 1 |
FORESTIER, J | 1 |
CERTONCINY, A | 1 |
GUENTHER, R | 1 |
OGUNI, S | 1 |
OKAMOTO, Y | 1 |
MATSUO, J | 1 |
YABUTA, K | 1 |
KADOMA, K | 1 |
KOVACS, L | 1 |
KOSZTOLNYIK, J | 1 |
TAKACS, B | 1 |
GAAL, K | 1 |
FORD, DK | 1 |
STEPAN, J | 3 |
KAKAC, B | 1 |
BYWATERS, EG | 1 |
MARKIEWICZ, K | 1 |
KRALOVA, M | 1 |
VOJTISEK, O | 1 |
MARSIKOVA, L | 1 |
PROKOPOVA, D | 1 |
KERUZORE, A | 1 |
COSTE, F | 1 |
DELBARRE, F | 1 |
LOUYOT, P | 1 |
GAUCHER, A | 1 |
MATHIEU, J | 1 |
METZ, R | 1 |
El aichaoui, S | 1 |
Amine, B | 1 |
Saoud, B | 1 |
Guedira, N | 1 |
Allali, F | 1 |
Hajjaj-Hassouni, N | 1 |
Wirth, W | 1 |
Diekmann, L | 1 |
Klokenbusch, S | 1 |
Skorobatskiĭ, VS | 1 |
Dolgopolova, AV | 1 |
Reuschel, I | 1 |
Reinelt, D | 1 |
Gruber, G | 1 |
Sigidin, IaA | 2 |
Lendle, L | 1 |
Bibikova, TI | 1 |
Hrncír, Z | 1 |
Nesterov, AJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis[NCT00302952] | Phase 2 | 64 participants (Actual) | Interventional | 2007-11-06 | Terminated (stopped due to Slow enrollment &Study Drug Expiration (Target: 40 randomized participants /arm)) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Blood draw for CRP, an acute phase reactant used to identify the presence of nonspecific inflammation. Change=Day 84 value minus Baseline value. Normal serum CRP reference range in this study is 0-4 mg/L (log transformed: -4.2 to 1.4). Participants with measurements for designated time points were included in analysis. An increased CRP level indicates the presence of inflammation. Reduced CRP levels could mean a decrease in inflammation. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | mg/L (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | -0.3 |
Anti-CCP antibodies are autoantibodies frequently detected in the serum of individuals with rheumatoid arthritis. In this study, a positive value for anti-CCP was 8 IU/mL or greater; a negative value for anti-CCP was <8 IU/mL. Change= subtraction of Day 0 from Day 84 anti-CCP value. In general, high levels of the antibody indicate an aggressive rheumatoid arthritis and a higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline ( Day 0), Day 84 (Wk 12)
Intervention | IU/mL (Mean) |
---|---|
Lovastatin 80 mg | 16.3 |
Placebo | -1.0 |
Rheumatoid factor (RF) is an antibody often present in the blood of a person with rheumatoid arthritis. In this study, a positive value for RF was 0.5 IU/mL or greater; a negative value for RF was <0.5 IU/mL. Change= Day 84 value minus Baseline value. In general, presence of the antibody indicates aggressive rheumatoid arthritis and higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | IU/mL (Mean) |
---|---|
Lovastatin 80 mg | -5.4 |
Placebo | 2.8 |
The DAS28-CRP score is on a scale of 0 to 10 and indicates current activity of rheumatoid arthritis (>5.1=high disease activity; 3.2-<=5.1=moderate disease activity; <=3.2=low disease activity; <2.6=remission). The score uses a combination of four variables: 1) the number of tender joints (of the 28 that are measured); 2) the number of swollen joints (of the 28 that are measured); 3) serum C-reactive protein (CRP) lab value in mg/L , and 4) Patient Global Assessment of Disease Activity. Using a formula, the physician determines the score. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0) to Day 84 (Wk 12)
Intervention | Scores on a scale (Mean) |
---|---|
Lovastatin 80 mg | -0.5 |
Placebo | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | U/L (Mean) |
---|---|
Lovastatin 80 mg | -2.4 |
Placebo | 8.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | % of packed red blood cells by volume (Mean) |
---|---|
Lovastatin 80 mg | -0.5 |
Placebo | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | pg (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | 0.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | fL (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | 0.7 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | % of mean corpuscle volume (Mean) |
---|---|
Lovastatin 80 mg | -0.4 |
Placebo | 0.2 |
Patients were ACR20 Responders if they had: at least 20% improvement in both tender joint count (28 examined) and swollen joint count (28 examined), and 20% improvement in at least three of the following 5 remaining ACR core measures: • Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm) • Patient's global assessment of disease activity (VAS 100 mm) • Physician's global assessment of disease activity (VAS 100 mm) • Patient self-assessed disability (Health Assessment Questionnaire (HAQ)) score • Acute phase reactant C-reactive protein. Participants with measurements for designated time points were included in analysis. (NCT00302952)
Timeframe: Day 84 (Wk 12)
Intervention | Percentage of participants (Number) |
---|---|
Lovastatin 80 mg | 29.0 |
Placebo | 40.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | g/dL (Mean) | |||
---|---|---|---|---|
Albumin | Total Protein | Hemoglobin | MCHC | |
Lovastatin 80 mg | 0.0 | 0.0 | -0.3 | -0.3 |
Placebo | 0.1 | 0.1 | -0.3 | -0.4 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | U/L (Mean) | ||
---|---|---|---|
Alkaline Phosphatase | ALT | AST | |
Lovastatin 80 mg | -3.0 | -1.8 | -1.2 |
Placebo | 0.4 | 0.7 | 0.8 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | 10^3/uL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
WBC | Neutrophils | Bands | Lymphocytes | Monocytes | Eosinophils | Basophils | Platelet Count | Reticulocytes | |
Lovastatin 80 mg | 0.1 | 0.2 | 0.0 | -0.1 | 0.1 | 0.0 | 0.0 | -8.2 | -4.7 |
Placebo | -0.4 | -0.6 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -5.6 | 0.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | mmol/L (Mean) | |||
---|---|---|---|---|
Potassium | Sodium | Chloride | Total CO2 | |
Lovastatin 80 mg | 0.0 | -0.2 | -0.1 | 0.7 |
Placebo | 0.0 | -0.2 | 0.5 | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
Intervention | mg/dL (Mean) | |||||
---|---|---|---|---|---|---|
Total Bilirubin | Creatinine | BUN | Phosphorus | Calcium | Glucose | |
Lovastatin 80 mg | 0.0 | 0.0 | -0.4 | 0.0 | 0.0 | -4.3 |
Placebo | 0.1 | 0.0 | -0.5 | 0.0 | 0.0 | -1.2 |
2 trials available for chloroquine and Acute Rheumatic Fever
Article | Year |
---|---|
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; | 2003 |
[On the mechanism of the therapeutic action of antirheumatic preparations].
Topics: Adrenal Cortex Hormones; Chloroquine; Clinical Trials as Topic; Collagen Diseases; Humans; Pyrazoles | 1967 |
23 other studies available for chloroquine and Acute Rheumatic Fever
Article | Year |
---|---|
Rheumatic fever; clinical and differential diagnosis.
Topics: Chloroquine; Humans; Rheumatic Fever | 1948 |
[Serological research in chronic inflammatory rheumatism; study of antistreptolysin O].
Topics: Antistreptolysin; Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Humans; Quinacrine; Research; | 1954 |
[On the resochin therapy of primary chronic polyarthritis rheumatica].
Topics: Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Rheumatic Fever | 1959 |
[Severe cases of rheumatic fever resistant to normal doses of steroid hormone preparations and methods of management].
Topics: Chloroquine; Disease Management; Humans; Prednisolone; Rheumatic Fever; Steroids; Triamcinolone | 1962 |
[Combined cases of Bechterew's disease].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Prednisolone; Rheumatic Fever; Spondylitis; S | 1962 |
NON-STEROID ANTIRHEUMATIC DRUGS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Biomedical Resea | 1964 |
DETERMINATION OF CHLOROQUINE IN URINE BY UV-SPECTROGRAPHY AND THE TYPES OF SPECTRA AFTER INTRAVENOUS INFUSION.
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Chromatography; Colorimetry; Drug Therapy; Infusions, | 1964 |
[DAMAGE DUE TO LONG-TERM THERAPY. 1. ANTIRHEUMATIC AGENTS].
Topics: Adrenal Cortex Hormones; Aminopyrine; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloro | 1964 |
CHILD CARE IN GENERAL PRACTICE. RHEUMATIC FEVER AND RHEUMATOID ARTHRITIS.
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Child Care; Chloroquine; D | 1965 |
[SIDE EFFECTS AND COMPLICATIONS FOLLOWING THE ADMINISTRATION OF QREEHIM].
Topics: Chloroquine; Drug Therapy; Rheumatic Fever; Toxicology | 1965 |
EOSINOPENIA AND ACTH-ELECTROLYTE TEST AFTER CHLOROQUINE DIPHOSPHATE INFUSION IN PATIENTS WITH ARTICULAR DISEASE.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therapy; Electrolyt | 1965 |
ON THE PROBLEM OF THE INTERFERENCE OF CHLOROQUINE WITH THE REGULATORY MECHANISMS IN MAN.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therap | 1965 |
[The treatment of inflammatory rheumatism by antimalarials (chloroquine and hydroxychloroquine)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Rheumatic Diseases; Rheumatic Fever | 1960 |
[Treatment of chronic inflammatory rheumatism with chloroquine and its derivatives].
Topics: Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Humans; Rheumatic Diseases; Rheumatic Fever | 1961 |
[Complete auriculoventricular block during chloroquine treatment].
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Female; Heart Block; Humans; Pacemaker, Artificial; | 2007 |
[Problems of disseminated lupus erythematosus in infants and children].
Topics: Arthritis, Rheumatoid; Azathioprine; Child; Child, Preschool; Chloroquine; Dermatomyositis; Female; | 1978 |
[Effect of quinoline derivatives on certain indicators of humoral immunity and streptococcal allergy in rheumatic patients].
Topics: Adult; Antibodies, Bacterial; Antibody Formation; Antistreptolysin; Chloroquine; Female; Humans; Hya | 1974 |
[Current aspects of treatment and prevention of rheumatic fever in children].
Topics: Aminopyrine; Aspirin; Benzoates; Child; Chloroquine; Humans; Immunosuppressive Agents; Indomethacin; | 1974 |
[Diagnosis and course evaluation in rheumatic fever].
Topics: Acute Disease; Adult; Aminopyrine; Child; Chloroquine; Humans; Penicillins; Phenylbutazone; Predniso | 1974 |
[Critical view on drug therapy for rheumatism].
Topics: Analgesics; Animals; Anti-Bacterial Agents; Chloroquine; Drug-Related Side Effects and Adverse React | 1967 |
[Results of long-term treatment of rheumatism with resoquine].
Topics: Adolescent; Adult; Chloroquine; Female; Humans; Male; Middle Aged; Rheumatic Fever; Time Factors | 1968 |
[Can chloroquine be used in the treatment of rheumatic fever and the prevention of recrudescence?].
Topics: Chloroquine; Humans; Rheumatic Fever | 1966 |
[Treatment of rheumatic fever].
Topics: Adrenal Cortex Hormones; Chloroquine; Humans; Pyrazoles; Rheumatic Fever; Rheumatic Heart Disease; S | 1966 |